Thedevelopment of anti-factorVIII (FVIII) antibodies is currently one of them ost seriousc omplicationsi nt he treatment of haemophilia Ap atients. Numerous studiesi nl iteraturer eport on theirepitope specificity,their mechanism of FVIII inactivation, and their relationship with FVIII genetic alterations.During the last twoy ears, however, ap articular effort has been made to better understand their generation,with particular emphasis on the interplay of Tcells and Bcells specific forFVIII and the generation of anti-FVIIIa ntibodies.Moreover, novels trategies to improvet he management or treatment of patients with antiFVIIIa ntibodies have been recentlyp roposed:the useo fl ess immunogenic engineered recombinant FVIII molecules, neutralKeywords Coagulation inhibitors, Factor VIII, haemophilia A ization of inhibitorsbyblocking their deleterious activity either by lowm olecular weight peptided ecoyso rb ya nti-idiotypic antibodies,a nd attemptst os uppresst he T-cell response involved in the antibody formation.All of these representpromising therapeutic approaches. This reviewa ttempts to sum up current knowledge of then ature and propertieso fa nti-FVIII antibodies,t heir mechanism of action, their neutralizationb y anti-idiotypicantibodies,and the role of Tcells in FVIII inhibitor formation.Inthe finalpart, some of thenew strategiessusceptibletoimprove the management or the eradication of anti-FVIII antibodiesare presented. 
Introduction
Factor VIII (FVIII)isacofactor in the generation of thrombin by the tenase complex at the surface of activatedplatelets. It is synthesized in the livera sa3 30-kDap recursor protein with an A 1 -a 1 -A 2 -a 2 -B-a 3 -A 3 -C 1 -C 2 domain structure, whichs ubsequentlyundergoes proteolytic processing. FVIII circulates in association with vonWillebrand factor (vWF)asaseries of heterodimers, consisting of aheavy chain(domains A 1 -a 1 -A 2 -a 2 and variable lengthso ft he Bd omain), and al ight chain( domains a 3 -A 3 -C 1 -C 2 )associatedvia metalion interaction.
Haemophilia Ai sa nX -linked bleeding disorderc aused by deficiencyorfunctional abnormality of FVIII,atafrequencyof about onei n5 ,000 men. Substitution of defective FVIII by human FVIII concentratesorbyrecombinantorplasma-derived FVIII representsthe basis of the treatment for haemophilic patients. One of the major threats facing patients treated with FVIII concentrates is the development of an immune response to FVIII. Antibodiesinhibiting FVIII activity,calledinhibitors, are observedin10% to 40% of patients (1) .According to their immunological setting, these inhibitors are qualifieda sa lloantibodies; when theya ppeari nt ransfused haemophilic patients, and as autoantibodieso ra cquired inhibitorsi np atients with autoimmune disease. Thefrequencyofthe latter is estimated to be one case per million each year.These patients with anti-FVIII antibodies( Abs)t hen become resistant to substitution therapy, and their management becomes amajor therapeutic challenge. Anti-FVIII Abs can be diagnosed either during routines cheduled surveillanceorbyasudden lackofresponsivenesstoFVIII replacement therapy.The presenceofanti-FVIII Abs, as well as their quantification, can be confirmed using the Bethesda assay, where oneBethesda Unit (BU) is defined as the inverse of the plasma dilutioninhibiting 50% of FVIII activity in normal plasma. Indeed,p reventing or suppressing inhibitors to FVIII re-mains ac hallenge for both clinicians and scientists. Ab etter understanding of the molecularand cellular basesofthis complication should leadtothe development of prophylatic means to prevent the onset of FVIII inhibitorsortherapeutic tools to limit their action. The aim of this article is to reviewcurrent knowledge on the natureand propertiesofthe different anti-FVIIIantibodies, their mechanism of action, their potential neutralization by anti-idiotypic antibodies, and to examine the important roleof Tcells in anti-FVIII antibodyformation. In the last paragraph, we discuss newstrategiesthat could represent promising therapeutic approaches for the management or the eradication of anti-FVIII antibodies.
Genetic properties of FVIII inhibitors
In an attempttoidentify some common features betweenthese inhibitors, the question of their eventual isotype or sequenceparticularitiesh as been addressedi ns everal studies. Most of the anti-FVIII Abs are of the IgG isotype.S ome IgM and IgA inhibitors have,however,been observed in patients with acquired haemophilia (2) . Gillese ta l. (3), whop urified alloantibodies from plasma by affinity chromatographyonFVIII, observedthat the isotypic distribution of anti-FVIIIAbs follows the physiologicalprofile of IgG subclasses. However, several other studies report aprevalenceofthe IgG 4 subclass (although IgG 4 constitutes only4%ofserum IgG) oftencombined with anothersubclass (primarilyIgG 1 )(4-6). It is interesting to note that the two human monoclonal Abs (MAbs),Bo2C11 and Le2E9, isolated from humanBcells, belong to the IgG 4 subclass (7, 8) . Someinhibitors of the IgG 3 isotype were reported,but this wasnever the casefor the IgG 1 or IgG 2 type.The light chains areeither κ or λ chaino rb oth (9) .The prevalent contribution of the IgG 4 molecules in the anti-FVIII Ab repertoiremight be explained by repeated FVIII infusions, although the underlying mechanism to explain this IgG 4 prevalenceremains to be elucidated.
To date,n oc omprehensive information on the gene repertoireusedtoencode anti-FVIIIAbs is available. Theonlyaccessible data are based on the characterization of the twoh uman MAbs, Bo2C11 and Le2E9 (7, 8) . In an attempt to obtain more information, Vo obergetal. (10)usedthe antibody phage display technology, where the patient'simmunoglobulin VH gene repertoires were cloned in aphage genome and then expressed in the formofscFvs (single chainantibody variable region fragments) at the surface of the phages. From their studies (11, 12) ,itappeared thatthe anti-C 2 Abs seem to useexclusively VH genes belongingtothe VH 1 family. However, depending on their epitope specificity,the VH gene of some anti-C 2 Abs is extensively modified by somatic hypermutations,and their CDR 3 loop is between 20 to 23 amino acids,whereasingeneral the averagelength is in the rangeof13amino acids (13) .Otheranti-C 2 Abs have aVH gene characterized by aC DR 1 and aC DR 2 being highly negatively charged (fiven egativec harges),ac haracteristic not affectedb yVDJ rearrangement norsomatic hypermutations.It should be notedthat the human anti-C 2 MAb Bo2C11 (8), whose VH gene belongs to the VH 1 family, exhibitst hese additional negative charges precisely in the CDR 1 and CDR 2 loops. These charges might mimic the negative surface of phospholipids (PLs)and interact with the positivelycharged ring of the C 2 domain, explaining howthis Ab inhibits the FVIII procoagulant activity by preventing the C 2 domain from binding to PLs. The 3D structureo ft he C 2 domain in complexw ith FabB o2C11 (14) confirms this assumption. Concerning the anti-A 2 and the anti-A 3 Abs,theyshowedabroader generepertoire, distributed amongV H 1 ,V H 3 ,V H 5 ,and VH 6 familiesa nd VH 1 and VH 3 families, respectively (11,1 2) . It is interesting to note that in spiteofthe fact thatsome anti-A 2 and anti-A 3 Abs useaVH gene belonging to theVH 1 family, theyshowdifferences in their somatic mutation profile as compared with the anti-C 2 scFvs, and theyd on ot present anyc ross-reactivity with the C 2 domain. Analysis of otheranti-FVIII Abs appearscrucial to establish precisely the rulesconcerning the VH gene repertoireuse of these Abs.
Origin of FVIIIinhibitors
Between 20%and 40% of patients with haemophilia Adevelop anti-FVIII alloantibodiesafter FVIII infusion. Theseinhibitors appear during the first monthsoftreatment,generally between the first and the fifthi njection (1).I nt he moderate and mild forms of the disease, the presence of endogenous FVIII reduces the inhibitor incidence; howeverthe risk of inhibitor formation might increase with the growing exposure to FVIII.The reason whyo nlys ome patients develop an immune response to FVIII still remains elusive.Indeed, several parameters have beenidentified whichseem to influencethe appearanceofanti-FVIII inhibitors.
Numerous studies have triedt oc orrelate genetic defects in the FVIII gene with inhibitor generation (15) .Patients with severe geneticlesions (16), i.e., nonsense mutations as well as important rearrangements (inparticular, intron 1orintron 22 inversions),h aveas trong risk of developingi nhibitors. These mutations lead, in the majority of the cases,eithertoalack of FVIII synthesis or to atruncated protein unable to be secreted (15) .The immune system of such patients, neverhaving been exposed to anyp eptide of the FVIII sequence, might be unablet oi nduce antigen-specific tolerance,t hus leading to the occurrence of FVIII alloreactive T/B cells. However, it is not yetp ossible to predict whichpatient will develop an inhibitor within this high risk group. In patients with small deletions,missense and splice site mutations, whichresultinloss of function butnot complete absence of FVIII protein, the inhibitor prevalencei sl esst han 10% (15, 17) . In this group, the patients arepartiallytolerant to the injectedFVIII because they are exposed to their ownendogenous FVIII.Consequently, the inhibitorsinthese subjects will inhibitt he injectede xogenous FVIII butn ot the self FVIII, whichisseen as aself-antigen(18). It should be noted,however, thatpatients with certain missense mutations also have atendency to develop an inhibitor.These inhibitors areprimarily targeted to the A 2 domain butalso to the C 1 -C 2 junction (19) . These mutations most probablygiverise to aconformationallyaltered protein predisposing to inhibitor development after exogenous FVIII administration. Certainassociations between specificmutations and the presenceofAbs have beenproposed (20). Similarly, arelationship between Ab occurrence and the localization of astop codon has been highlighted(20). Nevertheless, no definitive proof has beenr eported even if some mechanisms in connection with mRNA splicing are suspected to explain this observation (20). On the basis of the variousmutations indexedin HAMSTeRS database (http://europium.csc.mrc.ac.uk)( 20), it appearsthat: (i) patients with large gene deletions affecting more than one domain showahigherrisk of developinganinhibitor than those where only one domain is affected(74% of inhibitors for multi-domain deletions versus21% for singledomain deletions), (ii) the nonsense mutations affecting the FVIII light chain (29 inhibitorsassociatedwith 9different codons) are morefrequently associatedwith inhibitor development thanthose affecting the heavy chain (3 inhibitors for 3different codons). Thedifferent geneticdefectsare summarized in figure 1 . Nevertheless, in patients from the same familys howing as imilarF VIII mutation, not alld evelop an inhibitor,s uggesting that the occurrence of ap articularm utation in itself is not sufficient fori nhibitor development and thatotherfactorsare important too.
Some accompanying factorsare closelylinked to treatment: age at the beginning of FVIII treatment, FVIII level, interval between injected doses, and the natureo finjected FVIII.I ndeed, the composition and purity of the injected FVIII have beensuspected to have an influenceoninhibitor development as the different steps of purification and virus-inactivation of the FVIII preparationsmay modifythe physico-chemicalpropertiesofthe molecule and makeitmore immunogenic.Several cases of inhibitorappearance that could be directlylinked to the method of FVIII preparation have beenreported. Thefirst caseoccurred in Belgium and Holland,w herem ultitransfusedp atients usually treated with plasma-derivedFVIII concentrates suddenlydeveloped inhibitors when an ew FVIII preparation,i ncluding a supplementaryp asteurization step( CPS-P product),w as injected (21, 22) . Theseinhibitors recognizedspecificallythe C 2 domain, suggesting that the pasteurization step mayhavemodified the conformation of the C 2 domain, rendering it more immunogenic (23, 24) . The second series of cases waso bservedi n Germanyand Belgium in patients treatedwith aFVIII for which an additionals tepo fv iral inactivation by pasteurization was added (25).Itthus seems that the application of some viralinactivation methodsmay result in an important alteration of FVIII conformation, whichm ight lead to inhibitor generation.C oncerning the recombinantFVIII preparations (rFVIII), post-translational modifications specificfor each expression system used to preparethe therapeutic molecule somewhat modifyFVIII as comparedwith the native FVIII. Also,the absence of vWF during the manufacturing processm ay altert he spatial conformation of FVIII making it more immunogenic.I ndeed, in a comparatives tudy,w hose goal wast of ollowt he immune response in FVIIIknockout mice after injections of different FVIII concentrates(recombinantaswellasplasmatic FVIII), it appeared thatthe absence or the presenceofreduced levels of vWFcorrelated significantly witha ni ncrease in inhibitor generation (26) .This result,h owever,w as notc onfirmed in humans, and several studiesseem to showthat rFVIIIpresents an immunogenicity similar to that of plasma-derived FVIII (27) . Consequently, no clear association concerning the increase in the incidenceofthe inhibitors with specific FVIII concentrateshas been reported(28).
Other parameterspertain to the uniqueness of each patient. Inhibitor production is under the control of auxiliary Tc ells, namely FVIII-specific CD4+T cells. TheseauxiliaryTcells are subdividedinto Th 1 and Th 2 cells on the basis of their secreted cytokinep rofile (29). TheTh 2 cells are implicated in humoral immunity,a nd several observations tend to highlight their participation in the immune response directed against FVIII. Firstly, as mentioned,IgG 4 is the most commonlyencounteredsubclass among anti-FVIIIAbs (5),and Th 2 cells are necessary for subclassisotype switching,generating IgG unable to bind complement, thati s, IgEa nd IgG 4 (30) . Secondly, analysis of the primary sequences of the twohuman MAbs obtained by immortalization with the Epstein-Barr virus (7, 8) as well as thoseofthe human scFvs obtained by phage display (10) , indicates thatthey present several mutations as compared with the germline genes. This suggests thatthe Bcells producing anti-FVIII Abs undergo affinity maturation, as tepw hich requiresT -cell help ( 31) . Thirdly, amore direct proof of T-cellinvolvement wasthe observation of an inhibitor in haemophilia Apatients infected by HIV that disappeared when the T-cellnumber fell (32) .T-cell involvement hasi ntensively beens tudiedi na nimal models of haemophilia A. Twostrains of FVIII-deficient micegenerated by insertion of aneo geneinto the 3'end of exon 16 and exon 17 of the FVIII gene (probably blocking FVIII production after the A 3 domain), respectively were used (33, 34) . In these animals, human FVIII injections were followedb ythe generation of anti-FVIII Abs.B efore their detection, as ignificant proliferation of specificFVIII Tlymphocytes wasrecorded three days after the first FVIII injection (35) . Specificantibodies were observedin100% of the animals after twoorthreeinjections.This suggests that the antibody response to FVIII is T-celldependentand that the blockade of T-cella ctivation might prevent inhibitor antibody formation in haemophilia Amice. However, mored ifficulties were mettodemonstrate unequivocally FVIII-specific T-cellresponsesinhuman haemophilia Apatients. Several investigators (36-43) have triedtoisolate FVIII-specificCD4+ Tcells from peripheral lymphocytestoidentify immunodominant T-cellepitopes. To achievet his, theye xamined CD4+ T-cellr epertoires fromhaemophilia Apatients with and withoutinhibitors, from acquiredh aemophilia Ap atients and fromh ealthys ubjects. Somestudiesreported the use of whole recombinant FVIII and pools of peptides spanning whole domains of FVIII to stimulate proliferation of FVIII-specific Tcells (39, 40) , whereas other reliedono verlapping peptidesspanning onlyone precise domain (C 2 ,A 2 ,orA 3 ) (36, 41, 42) . These studies revealed thatall individualsp ossess CD4+ Tc ells thata re able to proliferatei nr esponse to FVIIIorFVIII peptides. SomeT-cell epitopesare common between groups, regardless of their inhibitor status, butthe occurrence of some other T-cellepitopes canbecorrelated with the presenceofaninhibitor.Similarlytothe restricted use of defined VH genesininhibitor,some V β genessuch as V β 2, V β 5, and V β 9usedbyT -cell receptors appeared to be moreoften expandeda mong inhibitor positive patients (40) .T -cell epitopes were identifiedinall domains of the protein. Moresurprisingly, several T-celle pitopes included residues that contribute to inhibitor binding sites, as shown by the work of Jacquemin et al. (37) , whoi solated and characterized T-cellc loness pecific for FVIII derived fromapatient with amoderate formofhaemophilia A(Arg 2150 His substitution in the C 1 domain) and showedthat both Bcells and Tcells recognized epitopeswithin the mutated region.
In an attempttoidentify individual factorsthat might affect inhibitor development, otheri nvestigatorsh avef ocusedo nt he study of the MHC class II moleculesinvolved in antibody generation, as these molecules present antigen-derivedp eptides (T-cell epitopes) to T-cellr eceptors ( 17) . This approachw as privilegedasseveral pieces of evidencetend to indicateapossible genetic predisposition for developinginhibitors. Indeed,inhibitor development is observedi na pproximately3 0% of patients with haemophilia A, and ethnic variationsare well documented (44) . Thus, depending on the inherited HLA haplotypes, onlycertain individualsare able to generate FVIII peptide-HLA moleculecomplexessusceptible to induce Abs directedagainst biologically relevant epitopes. However, studiesa imeda tp roving an association between definedHLA haplotypes and the capacity to elicit anti-FVIIIantibodies were notconclusive.Oldenburg et al. (45) as well as Hayetal. (46)were, nevertheless, able to demonstrate that in agroupofpatients with intron 22 inversion, the HLAh aplotypes A3,B 7, C7, DQA0102, DQBO602, and DR15 could be classed as risk allelesa nd haplotypes C2, DQA0103, DQB0603, and DR3, consideredincontrast as protective alleles.
Finally, anothere xplanation for the fact thati nhibitors are present onlyi nc ertain patients could be ad ifference in stimulation or suppression mechanisms thatregulate the immune response.For example, it hasbeen demonstrated thatanti-idiotypic Abs (Ab 2 )playarole in this regulation. In several cases of anti-FVIII autoimmune disease, aspontaneous remission wasassociated with an increased production of anti-idiotypic Absableto neutralize the inhibitorya ctivity of the anti-FVIII Abs (47) . Similarly, Gilles et al. (48) , and more recentlySakurai et al. (49) , suggested that the success of immune tolerance induction was associatedwith the development of anti-idiotypic antibodies, as the follow-up of the levelofanti-FVIII Abs in five unrelated haemophilia Apatients remained unchanged with time,whereasAb 2 were elicited. In asimplifiedmodel using the 20F2 monoclonal anti-idiotypicA bd irected againsta nti-FVIII autoantibodies from apatient, Dietrichetal. (50)established proof of the concept thatidiotype/anti-idiotype interactions represent aphysiological mechanism modulating the activity of anti-FVIII Abs,an observation whichwas laterconfirmed by Gilles et al. withtwo MAbs (51) .Finally, several groups (47, 52, 53) have shown that the inhibitoryactivity of natural anti-FVIII Abs in healthyindividuals canbeneutralized by anti-idiotypic Abs. Thus, anti-idiotypic antibodiesmay shift the immune systemtoward asteadystate equilibrium thatprevents immune response. Nevertheless, the current data do not allowustogeneralizethe conclusion that the de novo development of inhibitorsr esults from ad eregulation or adeficiencyofAb 2 production.
Localization of theepitopes
Many studieshavedealtwith epitope mappingofinhibitors in an attempt to understand their antigenic specificities. The first studieswere initiatedapproximately15years ago by Fulcher et al. ( 54) . By immunoblotting of thrombin cleaved FVIII, they showedt hat most of the epitopes recognizedb yt he inhibitors were localized within the FVIII light chaina sw ella si nt he 44-kDaf ragment,c orresponding to the A 2 domain, and more rarely withinthe 54-kDafragment,which corresponds to the A 1 domain (5).I ndeed, most of the FVIII mutations concernr esidueslocalized after the A 1 domain (55),sothat patients maysynthesize acertain percentage of protein showingacross-reactivity with the N-terminalpartofFVIII. More detailed epitope mapping waso btained by using recombinant FVIII fragments expressed in E. coli (56) .F rom this analysis it appeared thatt he light chain epitopes aremultiple with, however, apredominance Epitopes on the A 2 domain aree ssentiallyl ocalized in the N-terminal parto ft he domain, betweenr esidues3 79-538. Based on the observation thatc linically significant inhibitors usuallycross-react poorlywith porcine FVIII, Lollaretal. (57) elegantly mappedt he A 2 and C 2 domain epitopes. Indeed,b y using recombinant hybrid human/porcine FVIII fragments, they identifiedamino acidsubstitutions that resulted in adecreasein Ab cross-reactivity.Bytaking advantage of exceptionalpatient's plasma monospecific for the A 2 or C 2 domains, theywere able to identifythe human FVIII amino acids responsible for the noted antigenic differences. Thus, am ajor anti-A 2 domain wasn arrowedtoresiduesArg 484 -Ile 508 (58) .This antigenic region contains either au nique epitope recognizedb yt he anti-A 2 Abs or several overlapping epitopes. Alanine scanning of alla mino acids in the 484-508s equence thatd iffer between humana nd porcine FVIII showedt hat Ty r 487 plays ac rucial role in the A 2 epitope (59). However, a26-mersynthetic peptide corresponding to the human FVIII sequence Va l 483 -Glu 507 neutralizedonly weaklyF VIII inhibition by anti-A 2 Abs,s uggesting that other amino acids outside this region mayc ontribute to the epitope (58) .
Epitope localizationinthe C 2 domain is more complex. The use of human/porcine hybrids in the study of five human plasma samples and amonoclonalmurine Ab suggested that partofthe functional epitope recognizedbythe inhibitor waslocated near the N-terminalp arto ft he C 2 domain, within residues 2181 to 2243 (60) .Onthe other hand,anapproach basedonaseries of overlapping synthetic peptidesc overing the C 2 domain underlinedthe importanceofresidues2303 to 2332 in the C 2 epitope (61,62). These resultsare consistent with earlierones and suggest rather that amino acids present both in the N-and C-terminal parts of the C 2 domain takepartinformation of the epitope. It is possible since the crystallographic modelo ft he C 2 domain shows that both ends arei nc lose proximity,b eing linked by a disulfide bridge betweenCys 2174 and Cys 2236 (63) . An additional epitope in thelight chain, farapartfrom the C 2 domain, wasassignedbytwo independent studiesonthe A 3 domain. An approachbased on recombinant fragmentsshowedthat the region Gln 1778 -Met 1823 constituted partofthis epitope (64 In addition to these inhibitors, mainlyfound in patients, other anti-FVIIIAbs with more uncommon epitope specificities have beenidentified in certainsubjects. These specificities arelocalizedw ithin the different acidic regions( a 1 ,a 2 ,a nd a 3 ). Their mappingi sm ore difficulta st heya re notf requent (67) , and monospecificAbs against these regions arerare. Using murine MAbs, thought to be representative of human anti-a 1 Abs,several groups have shown thatthe sequence Thr 351 -Asp 361 appears to be the main epitope recognized in the a 1 region (67-69). The antigenicity of this region wasconfirmed by our group by characterizing anothermurine MAb (70) .The anti-a 3 Abs are more frequent (71) , and several studiesunderline their existence (66, 72, 73) . The effects of these inhibitors areadditive,suggesting that inhibitors to agiven domain act independentlyofinhibitors to other domains. From one patient to another, the epitope specificity can vary to aconsiderableextent. This epitopic complexity is further increased as the epitope profile mayc hange with time: inhibitors present in lowconcentrations at agiven time may become dominant later (74) .Anepitope spreading phenomenon has also beennoticed: some inhibitors having initiallyaspecificity for the A 2 domain later on recognize the C 2 domain (75) . Despite thedifferent immunologic settings in whichtheyarise, alloantibodiesand autoantibodies appear to bind to the same epitopes, though autoantibodies ared irected primarily against single domains (2).
Methods of FVIII inactivation
Aschematic representation of the different mechanisms of inactivation of anti-FVIII antibodiesisshown in figure 3 . Depending on their epitope specificities, anti-FVIIIAbs prevent FVIII from interacting with its variouspartners (PLs,vWF,FIX, or FX), thus impairing the coagulation cascade (Fig. 3-1) . Them ost documented inactivation mechanism is the inhibition of FVIII binding to PLs and vWF by anti-C 2 Abs.Indeedbyresolution of the crystallographic structureofthe C 2 domain, twoPLinteraction (72) reported the case of an anti-a 3 Ab, whichb ys terich indrance interferes with the interaction between FVIII and vWF,asthe acidic region a 3 contains the seconds ite of the vWFb indingm otif (77) .As vWF plays aprotective rolefor circulating FVIII,the inhibition of this interaction rendersFVIII more susceptible to proteolytic inactivation. ForFVIII interaction withFIX, twobindingmotifs were reported. Region1 811-1819 along the A 3 domain is responsible forthe high affinity for FIX, and region 484-508 of the A 2 domain is involved in the 100-foldincrease in the kcatofthe FX conversion to FXa (78) . Inhibition of this interaction is easily explained as the main epitopes of anti-A 3 Abs as well as anti-A 2 Abs are included or are confined withinFIX binding regions (64, 65, 79) . Moreover,the anti-A 2 Abs inhibitdirectly the interaction of the A 2 domain with the protease domain of FIX, whichresults in the decreaseofthe Vmax of the activation of FX to FXa by >95% at saturating concentrations without altering the Km (80) . Finally, concerning the interaction of FVIII with FX, antibodies directedagainst residues 2253-2270ofthe C 2 domain (81) and the acidic region a 1 (82)prevent this interaction.
Other inactivation mechanisms delaythe activation of FVIII by thrombin,acrucial step forthe procoagulant activity of FVIII. One mechanism is theslowingdownofthe dissociation of FVIII from vWF,w hereasthe second relies on masking the thrombin cleavage site by steric hindrance (Fig. 3-2) . Thev WF binding motif is composedoftwo sites, one in the C 2 domain and the second one in the acidic region a 3 (77) . FVIII activation by thrombin involves elimination of the a 3 region,leading to aconformational change in the C 2 domain, resulting in vWF release (83) .Inthe first case, some rare anti-C 2 Abs,e xemplifiedb yt he murine MAb ESH8 (62) and by some humananti-C 2 Abs,whose epitope belongs to the region 2218-2307 (84),seem to prevent the conformationals witch that follows a 3 elimination. FVIII thus preserves its strong affinity for vWF and is indirectlyp revented from binding to PLs (83) .This delayinFVIII release from vWF appears to be sufficient to allowFVIII inactivation by dissociation of the A 2 subunit from the dimer.Inthe second case, several Abs binding to the acidicregions a 1 and a 3 ,that areinclose proximity with the thrombin cleavage site, were reported to prevent FVIII proteolysis by thrombin by steric hindrance (75, 90).
Another recentlyd escribed inhibitorym echanism involves FVIII hydrolysis by anti-FVIII Abs endowed with proteolytic properties (85) (Fig. 3-4) . Lacroix-Desmazes et al. reported that this antibody-mediated proteolytic activity wasp resenti nt he IgG fraction of anti-FVIIIAbs and wasspecific for FVIII since these IgG were unable to degrade irrelevant proteins such as albumin or FIX and as normal polyclonal IgGdid not hydrolyse FVIII (85) .The authorsalso reported that13of24patients with FVIII inhibitorsh ad catalytic antibodiesi nt heir plasma, and theyf ound as tatistically significant correlation between the presence of FVIII-hydrolysing and the FVIII-inhibitorya ntibodies (86) .The kinetic parametersofFVIII hydrolysis as well as the estimatedquantity of these catalytic Abs in plasma suggest that afunctional role canbeallottedtothis phenomenon in FVIII inactivation, even if their biological relevance remains unclear.
It is important to note thatifinhibitors areidentified through their blocking activity,otheranti-FVIII antibodies mayexist that do not interferew ith the functional propertieso fF VIII. They could be detected by ELISA, and although their precisephysiopathological role is unknown,theycan be responsible for the increaseinFVIII clearance, throughthe capture of the FVIII-immunoglobulin complexesbyphagocytic cells of the reticuloendothelial system (87) (Fig. 3-3) . Another possibilityw ould be that theyfavour the interaction with the endocytic receptor,low density lipoprotein receptor-related protein (LRP). Indeed,t he A 2 ,A 3 ,a nd C 2 domains, that aret he main targets of the anti-FVIII Abs, were alsoidentified as interacting with LRP (88) (89) (90) (91) . Therefore,inhibitors mayinduce aconformational alteration of FVIII,allowinginteraction with the LRP,resulting in increased FVIII clearance. Nevertheless, this mechanism has not yetbeen demonstrated.
Futureperspectives
Considerable advances have beenmade in recent years in understanding variousf acetso ft he problem of anti-FVIIIA bs, although manyquestions still remain to be answered. In this final section, we report the most promisings tudies, whichm ight eventually lead to newstrategiestoreduce or ideally to eradicate the anti-FVIII antibodies. Improvements could be achieved by intervening at several levels: (i)b yt reating haemophilia Ap atients with less immunogenic FVIII molecules,(ii) by reducing the Ab titrebyblocking Ab binding to FVIII with peptide decoys mimicking anti-FVIII Ab epitopes, or (iii) by acting directly at the source by suppressing the B-cella nd/or T-cellr esponses, whichare involved in the Ab formation.
Theconcept of using less immunogenic FVIII molecule is already of actuality,assome patients arebeing treated with porcine FVIII (Hyate: C) (92), amolecule reported to be poorlycrossreactive withh uman anti-FVIIIa ntibodies (93) .T oo vercome drawbacks likethe development of anti-porcine FVIII Abs after exposure to porcine FVIII (94) ,and the possible transmission of viralagents (95) ,Lollar et al. (96) constructedactivehuman/porcine hybrid FVIII moleculesb yr eplacing the B-celle pitopes along the A 2 ,A 3 ,and C 2 domains with the homologous porcine sequence.B arrowe ta l. (66) h aved emonstrated that in vitro human anti-FVIIIA bs recognizedp referentiallyt he human FVIII molecule rather hybrid FVIII moleculessuggesting are-duceda ntigenicity of these hybrids. Nevertheless, reducedi mmunogenicity hasn ot yetb een reported. Thesen ew molecules mayalso be very interesting for clinical usebecausetheyretain fullprocoagulant activities. They can still be improvedbymodifying their T-cellepitopes to reduce or block the ability of Tcells to recognizethe molecule and to stimulate the B-cell response. Nevertheless, thereisarisk of losingcertain biochemical propertiesofFVIII or theintroduction of newepitopes. This approach is very encouraging although supplementary in vitro and in vivo studiesa re required beforeu sing these engineered FVIII molecules as therapeutics.
Currently,a ny approach susceptible to significantly reduce antibodytitres of the patients mayimprovethe medicalmanagement of this disease. As this complication is largelyantibody mediated,our group has proposedastrategybased on blocking the deleterious activity of these Abs by lowmolecular weight peptide decoys mimicking epitopesr ecognized by anti-FVIII Abs with the objectiveofrestoring normalprocoagulant activity (97, 98) . This concept wasvalidatedinasimplifiedmodel basedon the humaninhibitoryanti-FVIII MAb Bo2C11. Despitethe fact thatthis MAb is an extremelypotent inhibitor (7,000 BU/mg),a seriesofsmall peptides(12-mer) selectedbythe phage display technologywas shown to be able to restore FVIII procoagulant activity in amurine model of haemophilia Aafter injection with MAbBo2C11 (97).Moderate and mildhaemophilia Apatients with inhibitor could be morepronetobenefit from peptide-based therapy, insofarasthe anti-FVIIIimmune response of such patients appears to involveonlyalimitednumber of B-cell clones, the specificities of whichare directed essentiallyagainst the epitope corresponding to the region containing the FVIII mutation. In severe haemophilia Acases,although the immune response is usually moreheterogeneous, B-cellepitopes cluster to onlyalimitednumber of regions; consequentlyanoptimal combination of peptides to obtain a"universal"decoycould inhibitamajority of anti-FVIII Abs.Another advantage of this approachi st hat peptides arep oor immunogens due to their small size,a nd the immune system would probablyi gnore them. Nevertheless, usage of peptides in therapyi sg enerally challengedb yt heir short in vivo half-lifeconsequent to their susceptibilitytodegradation. Introduction of modifications to peptides, suchasthe replacement of La mino acids by Da mino acids or by unnatural amino acids may, however, be an alternative to obtain morestable analogues. Moreover,t hese epitopic peptides could be used to preparea ffinity chromatographyc olumns.I ndeed, some clinicians carry out plasmaphoresis to deplete the anti-FVIIIAbs, but the drawbackisthe lowspecificity of this operation. Removalof inhibitorsonaFVIII columnisconceivable, butsuch atechnique is very expensive due to the requirement for FVIII.Therefore, use of immobilizedantigenic peptides as affinity ligands maybe ag ood alternative to remove inhibitorsf rom patients' blood. Consequently, the use of peptide decoys maybeapromising new approach forthe neutralization of pathologic Abs.
Insteado ffightinge xisting anti-FVIIIa ntibodies, blocking their production by inducing anergy or deletion of FVIIIspecific Bcells would be particularly interesting. Onepossible approachreliesonimmunoregulation by anti-idiotypic Abs. Indeed,the idiotopes recognizedbythe Ab 2 at the surface of the inhibitors are alsodisplayedbysurfaceimmunoglobulins (sIg)of the corresponding Bc ells. Therefore, the Ab 2 -sIg interaction mayp revent the production of inhibitors or even lead to cell apoptosis (99) . Several linesofevidencemay simplify the feasibility of suchanapproach. Gilles et al. showedthat the 14C12 anti-idiotypicM Ab recognizedi diotopes expressed by several patients having anti-C 2 domain Abs. Moreover,a st he residues constituting these idiotopes belong to the Ab germline sequence (51) and the fact thatVan den Brink et al. (11, 12) demonstrated that all the VH genesofthe anti-C 2 Abs were from the VH 1 gene family, we can expecttofind a"universal idiotope"abletogenerateanAb 2 susceptible to bind to the majority of anti-C 2 Abs. Extrapolating thishypothesis to the anti-FVIIIAbs with different epitope specificities mayhowever be moredifficultsincetheir VH gene repertoires arelessrestricted. To improvetheir use, selected Ab 2 can be humanized to reduce their immunogenicity and can be engineered in suchaway thattheir Fc partinteracts with complement or with the Fcγ receptor present at the surface of natural killercells. Nevertheless, such an approachisdifficult sincethe B-cell repertoire is in constant renewal.
AnotherattractiveB-cell depleting approach reliesonthe use of the chimeric MAb rituximab, directeda gainst the CD20 antigen(100). Rituximab is essentiallybeing used successfully in patients with B-cellm alignancies. Nevertheless, Stasi et al. (101) reported its ability to deplete selective Bc ells in tenp atients with acquired haemophilia A. Thet reatment wasc ompletelyeffectivefor patients with lowinhibitor titre.For patients with high antibody titre,additional drugs such as cyclophosphamide were required to obtain afull and durableresponse.
In contrastw ith the B-cellp opulation, the T-cellp ool is relatively fixedatbirth. ConsequentlyFVIII-specific immunosupressivet reatmentsd irected againstt he CD4+ Tc ells that drive antibodyformation is apromising perspective.T -cell activation requires twosignals: one is basedonanantigen-specific interaction betweenthe T-cellreceptor and the peptide-MHCon antigenpresenting cells, and the otherinvolves interactions betweenr eceptorsa nd their ligands such as CD40/CD40L and memberso ft he B7 family( B7.1, B7.2) and their ligands CD28/CTLA4. Preliminary attempts in the murine modelo f haemophilia Aare quite encouraging.Qianetal. (102) focused on apotential link existing between Ab generation and these costimulation pathways. Theyshowedthat administration of an IgfusedC TLA4 protein (CTLA4-Ig) prevents initiation of Ab formation, and theyunderlined the criticalrole of the B7.2 ligand,b ut not B7.1, in anti-FVIIIA bg eneration in the mouse model. Furthermore,inhaemophiliacmicewith an established anti-FVIII immune response, injection of CTLA4-Ig prevented a furtherincrease in anti-FVIIIAbs. However, tolerance induction wasn ot achievedb ecausei nitiallyi mmune-suppressed mice rechallengedwith FVIII responded with anti-FVIII Abs.Inthe same time, Scandella et al. showedt hat blocking the CD40/CD40L pathway by aMAb specific for themurine CD40 ligand delayedanti-FVIII antibody formation and reducedantibody titresinchallengedmice, reflecting suppression of the primaryi mmune response (103) . In anothers et of observations, Reipert et al.r eported thatd uring treatment of haemophilic mice, the development of anti-FVIII Abs wasc ompletelyp revented via the blockage of CD40/CD40L interaction and that the induction of FVIII-specific Tcells wassuppressed (104-106).In ac linical trialc arried outw ith an anti-CD40L antibody, confirmatoryresults were obtainedinhumans. Anti-CD40L mayeffectively block anamnestic responses to FVIII.H owever,n o long-termtolerancewas induced (107) .
There are thus several differentongoing researchprograms thatare promising in the perspective of finding an efficient treatment to prevent development of anti-FVIII Abs.N evertheless, costimulation blockade impairs all T-celldependentimmune responses,a nd am ore selective approach, whichw ould target T cells of defined specificity,i sd esirable.E ncouragingly, in an autoimmune context, Appeletal. (108) demonstrated thatbivalent solubleMHC/peptide complexes, whichonlybind to T-cell receptors with the appropriate MHC/peptide specificity,induced anergy of antigenspecific Tcells. This selectiveapproach could be appropriate in the context of haemophilia Aasmore and more studies tend to identify "universal CD4epitopes".
